Compare KRT & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRT | ADCT |
|---|---|---|
| Founded | 2000 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 541.1M | 484.4M |
| IPO Year | 2019 | 2019 |
| Metric | KRT | ADCT |
|---|---|---|
| Price | $27.59 | $3.62 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $26.50 | $7.75 |
| AVG Volume (30 Days) | 72.4K | ★ 750.6K |
| Earning Date | 03-12-2026 | 03-10-2026 |
| Dividend Yield | ★ 6.50% | N/A |
| EPS Growth | 4.70 | ★ 30.86 |
| EPS | ★ 1.56 | N/A |
| Revenue | ★ $467,743,000.00 | $81,357,000.00 |
| Revenue This Year | $13.05 | N/A |
| Revenue Next Year | $8.11 | $68.29 |
| P/E Ratio | $17.76 | ★ N/A |
| Revenue Growth | 10.67 | ★ 14.85 |
| 52 Week Low | $20.61 | $1.05 |
| 52 Week High | $32.68 | $4.98 |
| Indicator | KRT | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 61.46 | 39.10 |
| Support Level | $27.27 | $3.25 |
| Resistance Level | $29.48 | $3.87 |
| Average True Range (ATR) | 0.96 | 0.27 |
| MACD | 0.25 | -0.06 |
| Stochastic Oscillator | 85.89 | 4.36 |
Karat Packaging Inc is engaged in the manufacturing and distribution of disposable products used in restaurants and food service settings. The company operates and evaluates its business as a single reportable segment which encompasses the manufacturing and distribution of a diverse range of single-use food and beverage service products made from materials such as plastic, paper, biopolymer-based, and other compostable forms. The company offers products for the foodservice industry, including food packaging, containers, tableware, cups, lids, cutlery, and straws. These products are available in plastic, paper, biopolymer-based and other compostable forms. Its product line includes a variety of brands such as Tea Zone, Karat, Karat Earth, and Total Clean.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).